<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03323879</url>
  </required_header>
  <id_info>
    <org_study_id>DELIGHT</org_study_id>
    <nct_id>NCT03323879</nct_id>
  </id_info>
  <brief_title>Combined LDR Boost and HDR Whole Gland</brief_title>
  <acronym>Delight</acronym>
  <official_title>Dominant Intraprostatic Lesion Boost With Focused LDR Brachytherapy (BT) Integrated to Whole Prostate HDR BT: Safety and Feasibility Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose finding Phase I/II study of combined focused LDR brachytherapy boost with&#xD;
      whole gland single fraction HDR for men with low and intermediate risk prostate cancer and&#xD;
      Dominant Intraprostatic Lesion (DIL) visible on multi parametric MRI. Patients will receive&#xD;
      19 Gy HDR to the whole gland with concurrent LDR brachytherapy boost to the DIL, in a&#xD;
      sequential dose escalation manner. Primary endpoints are early toxicity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will have low and intermediate risk prostate cancer with a dominant&#xD;
      intraprostatic lesion definable on multi parametric MRI (PIRADS 4 or 5). Patients will have&#xD;
      MR planned LDR focal brachytherapy to the DIL using iodine-125, while at the same time have&#xD;
      single 19 Gy delivered to the whole prostate using ultrasound directed high dose-rate&#xD;
      brachytherapy (HDR). The LDR boost dose will start at 50 Gy, and increase DIL dose in&#xD;
      sequential cohorts of patients up until a dose of 80 Gy. Up to 20 patients will be included.&#xD;
      Primary endpoint is toxicity at 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual&#xD;
  </why_stopped>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential dose escalation design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute urinary and rectal toxicity at 3 months as measured using NCI CTCAE v 4.0</measure>
    <time_frame>At 3 months</time_frame>
    <description>Acute urinary and rectal toxicity within the first 3 months as measured using NCI CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late urinary and rectal toxicity using NCI CTCAE v4.0</measure>
    <time_frame>3-monthly for first year, then 6-monthly until Year 5</time_frame>
    <description>Cumulative incidence of urinary and rectal toxicity beyond 3 months using NCI CTCAE v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life (HRQOL) changes</measure>
    <time_frame>3 monthly for first year, then annually year 1-5</time_frame>
    <description>Changes in HRQOL as assessed using Expanded Prostate Index Composite (EPIC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>will be reported at 5 years</time_frame>
    <description>biochemical disease-free survival using PSA nadir + 2 ng/ml definition (Phoenix)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Carcinoma Prostate</condition>
  <arm_group>
    <arm_group_label>LDR/HDR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRI planned LDR boost to DIL with concurrent whole gland 19 Gy HDR. LDR dose will be sequentially escalated from 50 Gy to 80 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>LDR/HDR</intervention_name>
    <description>Focal LDR to dominant lesion with whole gland 19 Gy HDR</description>
    <arm_group_label>LDR/HDR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed Adenocarcinoma of the prostate&#xD;
&#xD;
          -  Single PIRADS 4 or 5 lesion on multiparametric MRI&#xD;
&#xD;
          -  T1c-T2b on rectal exam&#xD;
&#xD;
          -  Gleason 3+3 and PSA &lt; 20ng/mL&#xD;
&#xD;
          -  Gleason 3+4 and PSA &lt;10ng/mL&#xD;
&#xD;
          -  Less than 50% of the cores positive in an untargeted prostate biopsy.&#xD;
&#xD;
          -  Prostate volume &lt; 60 cc&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Incapable or ineligible for MRI imaging&#xD;
&#xD;
          -  Previous trans-urethral resection of prostate (TURP)&#xD;
&#xD;
          -  Previous or current use of androgen deprivation&#xD;
&#xD;
          -  Baseline International Prostate Symptom Score (IPSS) &gt; 15&#xD;
&#xD;
          -  Evidence of distant or nodal metastasis&#xD;
&#xD;
          -  Disease that contraindicates treatment with radiation (e.g connective tissue disease)&#xD;
&#xD;
          -  Unsuitable for anesthesia due to comorbidity&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sunnybrook Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 12, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2017</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brachytherapy</keyword>
  <keyword>LDR</keyword>
  <keyword>HDR</keyword>
  <keyword>monotherapy</keyword>
  <keyword>focal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

